Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?

ORİGİNAL ARTICLE
ENDOCRINOLOGY & METABOLISM

ABSTRACT

OBJECTIVE: We aim to investigate whether the use of dipeptidyl peptidase inhibitors (DPP-4i) affects the severity of disease, hospital mortality, and 3-month post-discharge mortality in type 2 diabetes mellitus (T2DM) individuals with coronavirus disease 2019 (COVID-19) infection.

METHODS: The study included 217 patients with type 2 diabetes hospitalized due to COVID-19 between March and October 2020. The patients included in the study were divided into two groups those using DPP-4i and those not using DPP-4i. Demographic characteristics, laboratory parameters, accompanying risk factors, concomitant comorbidities, hospital mortality, clinical course, and 3-month post-discharge mortality were compared between the patients who used DPP-4i and those who did not use.

RESULTS: The duration of hospitalization was 10.96±9.16 days in the group using DPP-4i, 12.22±9.1 days in the group not using DPP-4i, and when both groups were evaluated together, it was determined as 11.91±9.11 days. The hospitalization periods were similar between DPP-4i users and non-DPP-4i users (p=0.384). The need for mechanical ventilation (p=0.478 OR 0.710 95% confidence interval [CI], 0.274–1.836) and high-flow nasal cannula (p=0.457, OR: 0.331, 95% CI: 0.41–2.67) were similar between DPP-4i users and non-users. It was determined that the mortality (p=0.208, OR: 0.409, 95% CI: 0.117–1.429) and 3-month post-discharge mortality (p=0.383) were similar in the group using DPP-4i and those not using DPP-4i.

CONCLUSION: This study demonstrated that the use of DPP-4i by patients with T2DM in catching COVID-19 does not affect the mortality due to COVID-19, the severity of COVID-19 disease, and 3-month post-discharge mortality.

Keywords: COVID-19; diabetes mellitus; dipeptidyl peptidase-4 inhibitors.

Cite this article as: Erol RS, Cil Sen E, Yener Ozturk F, Sarac Z, Kokoglu GL, Canat MM, et al. Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients? North Clin Istanb 2022;9(3):207–214.
Covid-19 mortality, which can lead to more severe illness and acute respiratory distress syndrome (ARDS). It has been believed that elevated DPP-4 expression in type 2 diabetes mellitus is the cause of high disease morbidity and mortality in Covid-19. Also, DPP-4 is defined as one of the spike glycoprotein receptors for severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). Due to these, DPP-4 inhibitors (DPP-4i) have sparked an interest [2–6].

DPP-4 was first shown in 2013 to be a functional receptor that provides entry to cells through the S1b domain of spike glycoprotein of Middle East respiratory syndrome coronavirus (MERS-CoV), which is genetically similar to COVID-19 [5, 7]. It is known that angiotensin-converting enzyme (ACE)2 is the SARS-CoV-2 spike glycoprotein receptor [8]. A study demonstrated a correlation between DPP-4 and ACE2, suggesting that both membrane proteins are involved in the pathogenesis of virus entry [9]. Coexpression of ACE2 and DPP4/CD26 as the receptors of spike glycoproteins may lead to hypothesizing that different human coronaviruses (CoV) target similar cells types in various human tissues and may explain the presence of similar clinical features in infected patients. It is believed that DPP-4 also functions as a receptor for the viral entry of SARS-CoV-2, which is genetically identical to MERS-CoV [4, 5, 10]. DPP-4 T-cell antigen, also known as CD26, is a cell surface protein expressed in many tissues and a soluble molecule found in serum/plasma fluids, as well [11, 12]. DPP-4 also plays a role in the immune system, besides providing glucose regulation by causing the degradation of incretins and increasing insulin secretion.

Furthermore, DPP-4i has been shown to have significant systemic anti-inflammatory effects, reducing the concentration of major inflammatory cytokines such as interleukin-6 (IL-6) [13]. Furthermore, in mouse models, sitagliptin, which is DPP-4i, has been found to suppress the lung injury caused by lipopolysaccharide by reducing the release of cytokines such as tumor necrosis factor-alpha and IL-6, and significantly reducing the hyper-pulmonary inflammation in acute lung injury [14]. DPP-4i promotes faster tissue healing by increasing stromal cell-derived factor (SDF)-1 levels [15, 16].

Accumulating evidence suggests that increased pro-inflammatory cytokine release, known as the “cytokine storm” triggered by the host immune response to SARS-CoV-2, is directly associated with the poor prognosis of COVID-19 [17, 18]. In this context, the hypothesis of whether DPP-4 inhibition increases susceptibility to COVID-19 infection and whether it reduces significant complications such as ARDS, which represents the leading cause of death in COVID-19 patients, has been brought up [19].

Among diabetic patients with COVID-19, the outcomes regarding the risk of progression to more severe forms of the disease and mortality rates between DPP-4i users and non-users are heterogeneous. While some of the studies have concluded that DPP-4i has positive effects on COVID-19 mortality and severe illness due to COVID-19 [20–22], some others have revealed that the use of DPP-4i has neutral or harmful effects [23–29] on these two phenomena. Our study aimed to investigate whether the use of DPP-4i affects severe disease, hospital mortality, and 3-month post-discharge mortality in T2DM individuals with COVID-19 infection.

**Highlight key points**
- The use of DPP-4i by patients with T2DM before COVID-19 does not affect the mortality due to COVID-19.
- The use of DPP-4i by patients with T2DM before COVID-19 does not affect the severity of COVID-19 disease.
- The use of DPP-4i by patients with T2DM before COVID-19 infection does not affect 3-month post-discharge mortality.
- The mortality due to COVID-19 in T2DM is 11%.

**MATERIALS AND METHODS**

It is a single-center, case-controlled, retrospective observational study. It was carried out with the approval of the ethics committee (no; 1760, date; December 22, 2020) of Sisli Hamidiye Etfal Training and Research Hospital by the ethical rules of the Declaration Helsinki and the national regulations on retrospective observational studies. Due to the retrospective study design, the requirement for informed consent was waived by the hospital ethics committee. Our study was also reviewed and approved by the Ministry of Health.

The data of 2196 patients hospitalized in Sisli Hamidiye Etfal Training and Research Hospital between March 2020 and October 2020 due to COVID-19 infection were analyzed. In this analysis, patients with T2DM were chosen based on their medical history or use of antihyperglycemic agents or DM criteria in the ADA guidelines [30].
Two hundred and seventeen patients with T2DM who were confirmed to have COVID-19 according to the reverse transcription-polymerase chain reaction test in nasal or pharyngeal swab samples were included in the study. Those with T1DM diagnosis and those who were younger than 18 years of age were excluded from the study. No other patient selection was applied in our research, and the patients of all ages and genders over 18 years of age were included in the study.

Data were obtained from electronic medical records. Demographic characteristics of patients such as age, gender, and body mass index (BMI), accompanying risk factors such as smoking, hypertension (HT), hyperlipidemia (HL), comorbidities such as cerebrovascular disease (CVD), coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), and cancer were recorded. In addition, laboratory parameters such as glucose, HbA1c, creatinine (Cr), alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, neutrophil/lymphocyte, lymphocyte, d-dimer, and procalcitonin (PCT) at the time of admission to the hospital were also recorded. Furthermore, data regarding the use of DPP-4i, oral antidiabetic drugs such as sulfonylurea, basal and bolus insulin, antihypertensive drugs such as angiotensin receptor blockers, ACE inhibitor, Ca channel blocker, beta-blocker, and data on the presence of an antiplatelet or warfarin use were collected before hospital admission.

Participants were divided into two groups regarding DPP-4i users and non-DPP-4i users. DPP-4i users were defined as patients using DPP-4i for at least 3 months before hospital admission to avoid including patients who were started on DPP-4i at discharge.

The total length of hospital stay was determined. Discharged patients were called one by one, and patients who died within 3 months after discharge were determined. Patients who needed mechanical ventilation and a high-flow nasal cannula were evaluated as severe illness due to COVID-19. The primary endpoint of the study was the need for mechanical ventilation and high-flow nasal cannula, the secondary endpoint was in-hospital mortality, and the tertiary endpoint was 3 months post-discharge mortality.

RESULTS
A total of 217 patients with T2DM, diagnosed with COVID-19 infection, were included in the study. Fifty-three of these were using DPP-4i. The primary demographic and clinical characteristics of both patient groups are shown in Table 1. The mean age of patients using DPP-4i was 63.9±12.2, while the mean age of patients not using DPP-4i was 62.0±12.9. There was no statistical difference between the two groups regarding age, gender, and BMI (p=0.332, p=0.326, and p=0.847, respectively). No difference was observed between the two groups in terms of other demographic characteristics (Table 1). We observed that the participants were relatively homogeneous when their demographic characteristics and vital findings were considered.

There was no difference between the two groups in terms of systemic blood pressure, vital findings such as HR max, and laboratory tests (Table 1). There was no difference between the two groups in terms of other comorbidities such as COPD, CVD, CAD, HT, HL, and cancer. As expected, treatment of patients using DPP-4i was often accompanied by metformin and/or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in accordance with the Society of Endocrinology and Me-
### Table 1. Demographic and clinical characteristics of patients

|                      | On DPP-4i | Not on DPP-4i | Total patients | p     |
|----------------------|-----------|---------------|----------------|-------|
| **Age (years)**      | Mean±SD  | Mean±SD       | Mean±SD       |       |
|                      | (n=53)    | (n=164)       | (n=217)        |       |
|                      | 63.9±12.2 | 62.0±12.9     | 62.5±12.7      | 0.339 |
| **Female/male**      | 24/29     | 87/77         | 111/106        | 0.325 |
| **BMI (kg/m²)**      | 30.49±6.52| 29.53±5.50    | 29.99±5.76     | 0.847 |
| **SBP (mmHg)**       | 125.81±16.82 | 124.18±16.27 | 124.58±16.38  | 0.34  |
| **DBP (mmHg)**       | 76.7±9.06 | 75.07±10.01   | 75.49±9.8      | 0.357 |
| **HR**               | 84±14     | 88.26±12.77   | 85.9±13.07     | 0.339 |
| **RR**               | 17.4±3.46 | 18.22±3.73    | 18.01±3.67     | 0.091 |
| **O₂ saturation**    | 94.19±3.94| 94.05±4.3     | 94.09±4.21     | 0.85  |
| **Smoker**           | 13 (24.5%)| 33 (20.12%)   | 46 (21.19%)    | 0.477 |
| **Comorbidities (%)**|           |               |                |       |
| Hypertension         | 60.4      | 64.6          | 63.6           | 0.576 |
| CAD                  | 20.8      | 27.4          | 25.8           | 0.334 |
| CVD                  | 7.5       | 3             | 4.1            | 0.227 |
| COPD                 | 7.5       | 6.7           | 6.9            | 0.834 |
| Hyperlipidemia       | 41.5      | 28.7          | 31.8           | 0.081 |
| Cancer               | 1.9       | 5.5           | 4.6            | 0.457 |
| **Medication (%)**   |           |               |                |       |
| Basal insulin        | 37.7      | 37.2          | 37.3           | 0.944 |
| Bolus insulin        | 24.5      | 31.1          | 29.5           | 0.362 |
| Sulfonylurea         | 15.1      | 11            | 12             | 0.422 |
| Metformin            | 81.1      | 61.6          | 66.4           | 0.009 |
| Thiazolidinedione    | 5.7       | 4.9           | 5.1            | 0.732 |
| SGLT-2 inhibitor     | 20.8      | 4.3           | 8.3            | <0.001|
| ACE                  | 20.8      | 22.8          | 22.3           | 0.752 |
| ARB                  | 17        | 14.6          | 15.2           | 0.679 |
| Ca channel blocker   | 15.1      | 27.4          | 24.4           | 0.069 |
| Beta-blocker         | 32.1      | 27            | 28.2           | 0.475 |
| Antiplatelet         | 34        | 31.7          | 32.3           | 0.760 |
| Warfarin             | 0.0       | 3.7           | 2.8            | 0.340 |
| **Laboratory findings** |       |               |                |       |
| Glucose (mg/dl)      | 199.23±75.88 | 192.77±91.89 | 194.32±88.17  | 0.278 |
| Hba1c (%)            | 8.71±2.22  | 8.29±2.13     | 8.37±2.14     | 0.423 |
| Lymphocytes (10³/μL) | 1390.57±693.17 | 1649.70±3401.06 | 1586.41±2976.09 | 0.864 |
| Neutrophil/lymphocytes | 4.19±3.57  | 4.83±4.67     | 4.67±4.43     | 0.752 |
| ALT                  | 30.51±28.01 | 30.60±32.29   | 30.57±31.23   | 0.962 |
| AST                  | 34.62±23.73 | 34.33±23.22   | 34.40±23.29   | 0.918 |
| LDH                  | 274.00±104.15 | 296.62±114.65 | 290.88±112.26 | 0.163 |
| Cr (mg/dl)           | 0.98±0.41  | 1.11±1.06     | 1.08±0.94     | 0.410 |
| CRP (mg/dl)          | 65.70±60.28 | 70.35±68.02   | 69.22±66.11   | 0.897 |
| Ferritin             | 317.13±436.31 | 356.40±572.54 | 346.44±540.52 | 0.831 |
| D-dimer              | 884.16±870.31 | 1082.01±1318.14 | 1034.25±1226.06 | 0.307 |
| Procalcitonin (ng/ml)| 0.28±0.70  | 1.13±8.30     | 0.92±7.26     | 0.635 |

SD: Standard deviation; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HR: Heart rate; RR: Respiratory rate; CAD: Coronary artery disease; CVH: Cerebrovascular disease; COPD: Chronic obstructive pulmonary disease; SGLT: Sodium-glucose cotransporter; ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blocker; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LDH: Lactate dehydrogenase; Cr: Creatinine; CRP: C-reactive protein; DPP-4i: Dipeptidyl peptidase inhibitor.
Erol et al., DPP-4 inhibitors treatment in diabetic patients with COVID-19 infection

211

Table 2. Duration and outcomes with T2DM and COVID-19 treated with DPP-4i and without DPP-4i

| Outcome (% | On DPP-4i | Not on DPP-4i | Total patients | p  |
|------------|-----------|---------------|----------------|----|
| Duration   |           |               |                |    |
| The time between first symptom and hospitalization, median (days) | 4.19±2.84 | 4.74±3.87 | 4.61±3.64 | 0.483 |
| Hospitalization time, median (days) | 10.96±9.16 | 12.22±9.10 | 11.91±9.11 | 0.384 |
| Outcome (% |           |               |                |    |
| High-flow nasal cannula | 1.9       | 5.5           | 4.6           | 0.457  |
| Mechanic ventilation   | 11.3      | 15.2          | 14.3          | 0.478  |
| Death                 | 5.7       | 12.8          | 11.1          | 0.208  |
| 3-month post-discharge mortality | 6         | 3.49         | 4.14          | 0.383  |

About 9.8% (n=217/2196) of the patients hospitalized due to COVID-19 infection had T2DM, and the mortality of these T2DM patients was 11.1% (n=24). The duration of hospitalization was 10.96±9.16 days in the group using DPP-4i, 12.22±9.1 days in the group not using DPP-4i, and when both groups were evaluated together, it was determined as 11.91±9.11 days. The hospitalization period was similar between DPP-4i users and non-DPP-4i users (p=0.384).

The need for mechanical ventilation (p=0.478 odds ratio [OR] 0.710 95% confidence interval [CI], 0.274–1.836), and high-flow nasal cannula (p=0.457, OR: 0.331, 95% CI: 0.41–2.67) were similar between DPP-4i users and non-users. It was determined that the mortality was similar in the group using DPP-4i and those not using (p=0.208, OR: 0.409, 95% CI: 0.11–1.429) (Table 2, 3).

OR values for the need for high-flow nasal cannula, and mechanical ventilation, mortality in hospitalization, and 3 months post-discharge mortality were similar before and after PSM (Table 3).

No correlation was found for CRP, LDH, lymphocyte, D-dimer, ferritin, and PCT values measured at the time of admission to the hospital, with in-hospital mortality and for the need for high-flow nasal cannula and mechanical ventilation.

DISCUSSION

We found that the mortality rate, the need for a high-flow nasal cannula, and the need for mechanical ventilation were similar between the patients who used DPP-4i and did not use DPP-4i. According to the results of our study, using DPP-4i before COVID-19 infection does not af-
fect the mortality due to COVID-19 and the severity of COVID-19 infection. About 9.8% of the patients hospitalized due to COVID-19 infection had T2DM, and the mortality rate of these T2DM patients was 11.0%.

In a population-based study conducted in the UK that included 2.85 million T2DM patients, it was found that the use of DPP-4i slightly increased the risk of mortality [29]. They attributed this increased risk to prescribing DPP-4i mostly in older and more fragile patients. Advanced age is an independent risk factor for clinical outcomes associated with COVID-19. When we look at the study, we see that more than 50% of the patients using DPP-4i are reported to be over 65 years old. In our study, the mean age of the patients who used and did not use DPP-4i was below 65 years.

Contrary to our study, in a population-based study carried out in Turkey, including 9100 patients, it was observed that the use of DPP-4i (OR 0.57) decreased the mortality rate due to COVID-19 when compared to those who did not use DPP-4i [21]. In the study, the Cr clearance of those who did not use DPP-4i was found to be statistically lower than those who used DPP-4i. In our study, there was no statistical difference between the Cr values of the patients. Lower Cr clearance in non-DPP-4i users may be the reason for the increased mortality in non-DPP-4i users compared to DPP-4i users. In addition, the small number of patients in our study, different demographic characteristics, and concomitant comorbidities may have caused our results to be different.

Regarding T2DM patients with COVID-19 infection, the Sitagliptin treatment group and the group receiving standard treatment were compared in a case-controlled non-randomized study called sitagliptin in diabetic patients with COVID-19, which differs from our study in that the use of DPP-4i was used during the hospitalization period, not before hospitalization. It was shown that mortality in the group using sitagliptin, which is a DPP-4i (hazard ratio 0.44), decreased when compared to the standard treatment group [22]. DPP-4i therapy during Covid-19 infection may have improved the study results (Covid-19 related mortality and morbidity). Consistent with our study, in an observational study conducted in France, including 1166 patients, it was determined that there was no relationship between the use of DPP-4i and mortality due to COVID-19 [28]. The lack of positive effects on mortality due to COVID-19 and severe disease related to COVID-19 may be due to the ineffectiveness of DPP-4i on the soluble form of DPP-4.

Due to the heterogeneity of studies evaluating the effects of DPP-4i use on death and severe illness due to COVID-19, various meta-analyses have been made in a short time. Two meta-analyses revealed that there was no significant difference occurring with the use of DPP-4 inhibitors before hospital admission regarding the risk of developing a severe or fatal disease course in COVID-19 patients (risk ratio: 1.15; 95% CI: 0.64–2.06, risk ratio: 0.81; 95% CI: 0.57–1.15) [32, 33]. In the recent meta-analysis, which examined the most significant number of studies to date, 66,914 patients were evaluated and it was determined that the use of DPP-4i had no statistical significance on mortality [34].

The effects of DPP-4i on in-hospital morbidity and mortality due to COVID-19 have been the main focus. There are no studies on the long-term consequences of the use of DPP-4i on the health of discharged patients. Multiple organ damage affecting the liver, kidneys, and heart, which can eventually result in organ failure, is quite common among COVID-19 patients in intensive care units [35]. SARS-CoV-2 either induces new cardiac pathologies such as myocarditis and/or exacerbates the existing ones [36], and this points to the potential long-term cardiovascular effects of COVID-19. These phenomena may be important for diabetic patients who already have reduced lung, heart, and kidney function and may make them particularly susceptible to cumulative organ damage during SARS-CoV-2 infection [37]. Recently, Smelcerovic et al. [37] suggested that DPP-4i may be effective in the prevention and treatment of pulmonary fibrosis, heart, and kidney damage. They claimed that DPP-4i will achieve these effects by increasing SDF-1, which provides an increase in endothelial progenitor cells, improves the result of functional myocardial reparation, and has pleiotropic anti-inflammatory effects. For these reasons, although it was not objective, the wellness of the patients in the 3-month post-discharge period was questioned in our study. The 3-month post-discharge mortality of those who used DPP-4i and those who did not use DPP-4i were found to be similar.

Depending on the cytokine storm caused by the excessive immune response, inflammatory markers such as PCT, ferritin, D-dimer, and CRP may increase in patients with COVID-19, depending on the severity of the disease [38–40]. We did not detect any difference in inflammatory markers such as PCT, ferritin, and CRP between the patients who used DPP-4i and those who did not use it.
Our study has several limitations. First and foremost is that the small number of patients may have prevented our statistical significance. In addition, being a single-centered study with an observational design is the other limitation of our study. However, when the data in our study are evaluated, the patients using and not using DPP-4i are relatively homogeneous in terms of demographic characteristics, concomitant comorbidity, laboratory findings, and diabetes regulation. The homogeneity of the groups is a strong feature of our study.

**Conclusion**

As a result, this study demonstrated that the use of DPP-4i by patients with T2DM in catching COVID-19 does not affect the mortality due to COVID-19, the severity of COVID-19 disease, and 3-month post-discharge mortality.

**Ethics Committee Approval:** The Sisli Hamidiye Etfal Training and Research Hospital Clinical Research Ethics Committee granted approval for this study (date: 22.12.2020, number: 1760).

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**Authorship Contributions:** Concept – YA, RSE; Design – RSE, ECS; Supervision – RSE, FYO; Data collection and/or processing – ZS, GLK; Analysis and/or interpretation – RSE, YA; Literature review – DY, YE; Writing – RSE; Critical review – MMC, DYS.

**REFERENCES**

1. World Health Organization. Weekly epidemiological update- October 2021. Coronavirus (COVID-19) Dashboard. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-26-october-2021. Accessed Oct 26, 2021.

2. Targher G, Mantovani A, Wang XB, Yan HD, Sun QF, Pan KH, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab 2020;46:335–7. [CrossRef]

3. Singh AK, Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. Diabetes Res Clin Pract 2020;165:108266. [CrossRef]

4. Li Y, Zhang Z, Yang L, Lian X, Xie Y, Li S, et al. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. iScience 2020;23:101400. [CrossRef]

5. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glyc an shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 2020;9:601–4. [CrossRef]

6. Basseindine MF, Bridge SH, McLaughan GW, Gorrell MD. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12:649–58. [CrossRef]

7. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495:251–4. [CrossRef]

8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. [CrossRef]

9. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 2020;526:135–40. [CrossRef]

10. Pan K, Ohnuma K, Morimoto C, Dang NH. CD26/dipeptidyl peptidase IV and its multiple biological functions. Curesus 2021;13:e13495.

11. Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes Metab 2021;47:101213. [CrossRef]

12. Bouhanick B, Cracowski JL, Faullie JL; French Society of Pharmacology, Therapeutics (SFPT). Diabetes and COVID-19. Therapie 2020;75:327–33. [CrossRef]

13. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076–82. [CrossRef]

14. Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2018;315:L834–45. [CrossRef]

15. Zhong J, Rajagopalan S. Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 axis: implications for cardiovascular disease. Front Immunol 2015;6:477. [CrossRef]

16. Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smercerovic A. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2016;167:100–7. [CrossRef]

17. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol 2021;93:250–6. [CrossRef]

18. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol 2020;11:1708. [CrossRef]

19. Bielka W, Prazek A, Pawlik A. Therapy of type 2 diabetes in patients with SARS-CoV-2 infection. Int J Mol Sci 2021;22:7605. [CrossRef]

20. Rhee SY, Lee J, Nam H, Kyoung DS, Shin DW, Kim DJ. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. Diabetes Metab J 2021;45:251–9. [CrossRef]

21. Emral R, Haymana C, Demirci I, Tasci I, Sahin M, Calak E, et al. Lower COVID-19 mortality in patients with type 2 diabetes mellitus taking dipeptidyl peptidase-4 inhibitors: results from a Turkish nationwide study. Diabetes Ther 2021;12:2857–70. [CrossRef]

22. Solerte SB, D’Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care 2020;43:2999–3006. [CrossRef]

23. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 2020;43:1399–407. [CrossRef]

24. Kim MK, Jeon JH, Kim SW, Moon JS, Cho NH, Han E, et al. The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea. Diabetes Metab J 2020;44:602–13. [CrossRef]

25. Fadini GP, Morieri ML, Longato E, Bonora BM, Pinelli S, Selmin E, et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab 2020;22:1946–50. [CrossRef]
26. Meijer RI, Hoekstra T, van den Oever NCG, Simsek S, van den Bergh JP, Douma RA, et al; Amsterdam UMC COVID-19 biobank study group, Smits MM. Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands. J Diabetes Metab Disord 2021;20:1–6. [CrossRef]

27. Dalan R, Ang LW, Tan WYT, Fong SW, Tay WC, Chan YH, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother 2021;7:e48–51. [CrossRef]

28. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al; CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500–15. [CrossRef]

29. Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 2021;9:293–303. [CrossRef]

30. Addendum. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15–33. [CrossRef]

31. The Society of Endocrinology and Metabolism of Turkey [SEMT], Clinical practice guideline for diagnosis, treatment and follow-up of diabetes mellitus and its complications – 2019 (12th Ed). Ankara, TR: Miki Printing and Publishing; 2019.

32. Kow CS, Hasan SS. A meta-analysis on the precondition use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19. Therapie 2021;76:361–4. [CrossRef]

33. Bonora BM, Avogaro A, Fadini GP. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest 2021;44:1379–86. [CrossRef]

34. Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, et al. Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: a systematic review and meta-analysis. Arch Med Res 2022;53:186–95. [CrossRef]

35. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9. [CrossRef]

36. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020;5:831–40. [CrossRef]

37. Smelcerovic A, Kocić G, Gajic M, Tomovic K, Djordjevic V, Stankovic-Djordjevic D, et al. DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by COVID-19: a therapeutic approach of choice in type 2 diabetic patients? Front Pharmacol 2020;11:1185. [CrossRef]

38. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020;14:1753466620937175. [CrossRef]

39. Yonas E, Alwi I, Pranata R, Huang I, Lim MA, Yamin M, et al. Elevated interleukin levels are associated with higher severity and mortality in COVID-19 - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14:2219–30. [CrossRef]

40. Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care 2020;24:525. [CrossRef]